Anebulo Pharmaceuticals, Inc. (ANEB)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-02-12

Key Insights

Anebulo Pharmaceuticals reported Q4 2025 financial results, with details on revenue, expenses, and cash position.
The company provided a business update, highlighting key developments and milestones for its pipeline of drug candidates.
The filing indicates Anebulo is an emerging growth company, which may provide certain regulatory and reporting exemptions.

Quarterly Report Filed: 2026-02-12

Key Insights

Anebulo Pharmaceuticals reported a net loss of $X.X million for the quarter ended December 31, 2025, indicating ongoing development expenses for their lead drug candidate.
The company raised $X.X million through a private placement in December 2024, providing additional runway to advance their research and development efforts.
Anebulo's stock incentive plan was expanded in April 2025, potentially signaling plans to attract and retain key talent as the company progresses.

Current Report Filed: 2026-02-06

Key Insights

Anebulo Pharmaceuticals is voluntarily delisting its common stock from the Nasdaq Capital Market and terminating its registration with the SEC to suspend its reporting obligations.
The company cites the reason for the delisting and deregistration as having fewer than 300 shareholders of record.
This move will likely reduce compliance costs and reporting requirements for the company, but it also means the stock will no longer be publicly traded on a major exchange.

Current Report Filed: 2026-01-29

Key Insights

The company announced the final results of its previously announced tender offer, in which it accepted 300,000 shares of its common stock at a purchase price of $3.50 per share, representing approximately 0.73% of the outstanding shares.
The tender offer was oversubscribed, with a total of 4,907,881 shares properly tendered and not properly withdrawn, indicating strong investor interest in the company.
The shares accepted for purchase will be paid for in cash, without interest, and the remaining shares tendered but not purchased will be returned to investors.

Current Report Filed: 2026-01-27

Key Insights

Anebulo Pharmaceuticals announced the preliminary results of its tender offer to repurchase up to 300,000 shares of its common stock at $3.50 per share, which was oversubscribed.
The company expects to accept 300,000 shares for payment, representing approximately 0.73% of the outstanding shares as of January 26, 2026.
The tender offer was a proactive capital allocation decision by Anebulo to return cash to shareholders.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.